Bone Mineral Density
Delays between denosumab injections may worsen BMD response
A longer interval between denosumab injections is associated with suboptimal bone mineral density response at the spine and total hip, and strategies to improve the timely administration of denosumab in real-world settings are needed, according to findings published in The Journal of Clinical Endocrinology & Metabolism.
Air pollution contributes to low bone mineral content, BMD
Glucocorticoid therapy may reduce bone density in congenital adrenal hyperplasia
Liraglutide shows antiresorptive effect on bone in type 2 diabetes
A cohort of adults with type 2 diabetes assigned the GLP-1 receptor agonist liraglutide for 26 weeks experienced a preservation in hip and spine bone mineral density and no changes in bone resorption markers despite weight loss, suggesting the drug may have an antiresorptive effect, according to findings published in Bone.
Bone changes during menopause transition may signal future fracture risk
Faster increases in bone turnover during the menopause transition and greater bone turnover during early postmenopause are risk factors for fracture, even among women with relatively preserved bone mineral density, according to findings published in The Journal of Clinical Endocrinology & Metabolism.